U.S. Personal Products Stock News

Earlier this week, Bruker Corporation unveiled major upgrades across its spatial biology and proteomics portfolio, including the PaintScape 3D genome visualization platform, the CellScape XR spatial proteomics system, Functional Proteomics 2.0 workflows on timsOmni, and a new Spatial Biology Center of Excellence with the University of Glasgow. Together, these launches and collaborations deepen Bruker’s presence in high-content multiomics and translational research tools, potentially...

In February 2026, Belden Inc. reported past fourth-quarter 2025 sales of US$720.12 million and net income of US$67.89 million, alongside full-year 2025 sales of US$2.72 billion and net income of US$237.52 million, while outlining first-quarter 2026 guidance and confirming continued share repurchases. The combination of higher earnings, ongoing buybacks totaling US$154.91 million for 1.35 million shares, and an active M&A agenda underlines Belden’s focus on long-term value creation. With...

Why CMS Energy (CMS) is on investors’ radar today CMS Energy (CMS) has not been driven by a single headline event recently, but its recent share performance and fundamentals give investors several concrete data points to weigh. The stock’s recent returns span a mixed short term picture and a stronger longer term track record. CMS is up 0.6% over the past day, has slipped about 0.6% over the past week, and is higher by 7.9% over the past month. Looking further out, the total return stands at...

In February 2026, Rumble Inc. announced that its short-form video feature, Rumble Shorts, had been approved by Google Play, allowing Android users worldwide to download or update the app to access the new format. This move extends Rumble's short-form offering to a larger mobile audience while aiming to maintain the platform's freedom-first positioning in an increasingly competitive video landscape. Now we'll examine how expanding Rumble Shorts to Android users could influence Rumble's...

Tyra Biosciences recently announced that two clinical abstracts on its precision FGFR3 inhibitor TYRA-300 in metastatic urothelial cancer and non-muscle invasive bladder cancer were accepted for presentation at the 2026 ASCO Genitourinary Cancers Symposium. This acceptance highlights growing clinical and scientific interest in TYRA-300’s potential role across distinct bladder cancer settings, a central pillar of Tyra’s pipeline. Against this backdrop, we’ll explore how TYRA-300’s ASCO GU...

Rollins, Inc. recently reported higher fourth-quarter and full-year 2025 earnings, continued to signal a healthy M&A pipeline, and earlier this month presented its outlook at Barclays’ 43rd Annual Industrial Select Conference in Miami. Management’s emphasis on recurring revenue, disciplined acquisitions, and confidence in funding further deals after investing almost US$900 million over three years highlights how central M&A has become to Rollins’ growth ambitions. We’ll now examine how...

Plexus overview after recent trading move Plexus (PLXS) has drawn fresh attention after a recent move in its share price, with the stock last closing at $197.55. That level reflects a 1 day return of about a 0.5% decline and a 7 day return of roughly a 1.9% decline. See our latest analysis for Plexus. While Plexus has seen a modest 1 day share price pullback and a softer 7 day share price return, the 30 day share price return of 13.52% and 90 day share price return of 38.52% sit alongside a 1...

Neurocrine Biosciences (NBIX) is back in focus after reporting fourth quarter and full year 2025 earnings, alongside fresh 2026 sales guidance for INGREZZA and optimistic commentary around its late stage pipeline. See our latest analysis for Neurocrine Biosciences. At a latest share price of US$128.38, Neurocrine Biosciences has seen short term share price pressure, with a 30 day share price return of a 5.73% decline and a 90 day share price return of a 10.56% decline. However, a 1 year total...

Recent filings show Battery Management Corp. and Solel Partners LP expanding their positions in Braze (BRZE), even after a sharp share price pullback. This puts institutional behavior in focus for anyone tracking the stock. See our latest analysis for Braze. At a latest share price of $15.79, Braze has seen a sharp reset, with a 30 day share price return of a 37.14% decline and a 1 year total shareholder return of a 59% loss, indicating momentum that has been fading even as revenue and...

Why ICU Medical is back on investors’ radar ICU Medical (ICUI) has moved back into focus after resolving a longstanding FDA warning letter tied to its Smiths Medical business and posting fourth quarter results with adjusted earnings above analyst expectations, along with 2026 guidance that came in ahead of consensus. The company paired these updates with detailed 2026 earnings guidance, giving investors clearer visibility into expected GAAP net income of US$26 million to US$44 million and...

CVR Energy stock snapshot after recent performance CVR Energy (CVI) has been on many investors’ radars after a mixed run, with the share price up about 1.7% over the past day but showing weaker returns across the past week and month. At a last close of US$21.07, CVR Energy sits below its past 3 months level, with the stock also reflecting a negative year to date return and a weaker 3 year total return. See our latest analysis for CVR Energy. The recent 1 day share price gain contrasts with...

Applied Optoelectronics (AAOI) shares have been in focus after a run to nine year highs, with investors reacting to a cluster of events around earnings, new data center products, and fresh manufacturing capacity. See our latest analysis for Applied Optoelectronics. The recent run has been sharp, with a 51.06% 1 month share price return and a 137.40% 3 month share price return as investors react to earnings anticipation, new AI focused data center products, and the Texas capacity expansion...

On 17 February 2026, Bernstein Litowitz Berger & Grossmann LLP filed a class action alleging that Express Scripts, Cigna, and Evernorth diverted billions in drug rebates to a Swiss affiliate, Ascent, using disguised “fees” and formulary decisions that allegedly favored higher-paying drug manufacturers over lower-cost alternatives. The lawsuit directly challenges how Express Scripts and its parent Cigna structure and disclose PBM rebate economics, raising complex questions about fiduciary...

Breach Inlet Capital Management previously disclosed increasing its stake in Hilton Grand Vacations by purchasing 63,548 shares, while the company highlighted continued club member growth and contract sales strength across its timeshare platform. This combination of a larger institutional position and a broad, recurring-revenue membership base underscores how investor interest intersects with Hilton Grand Vacations’ integrated timeshare, financing, and resort operations model. We’ll now...

Sun Communities, Inc. recently approved an increase in its quarterly distribution to US$1.12 per common share and unit, up US$0.08 or about 8% from the prior US$1.04, implying an annual rate of US$4.48 per share beginning with the first-quarter 2026 payout, subject to ongoing Board approval each quarter. This higher distribution, announced alongside interim finance leadership returning to a familiar executive, highlights the company’s emphasis on income generation and continuity in its...

Trinity Industries (TRN) is back in focus after its latest quarterly results and 2026 earnings outlook, which highlighted higher net income and earnings per share along with lower sales compared with the prior year. See our latest analysis for Trinity Industries. At a share price of $34.60, Trinity Industries has given investors a 28.0% 1 month share price return and 31.2% 3 month share price return. Its 1 year total shareholder return of 19.4% points to momentum that has been building rather...

Americold Realty Trust, Inc. reported fourth-quarter 2025 results showing sales of US$600.68 million and revenue of US$658.45 million, with net loss widening to US$88.34 million and loss per share from continuing operations at US$0.31. Alongside these weaker results, the company introduced a new Chief Financial Officer, Chris Papa, and set out a detailed 2026 plan focused on balance sheet repair, cost reductions, and targeted growth in higher-value cold storage segments. Next, we’ll examine...

Ultra Clean Holdings, Inc. reported fourth-quarter 2025 revenue of US$506.6 million, down from US$563.3 million a year earlier, and moved from net income of US$16.3 million to a net loss of US$3.3 million, contributing to a full-year 2025 loss of US$181.2 million on slightly lower annual revenue of US$2.05 billion. Despite the swing to losses, the company guided first-quarter 2026 revenue to US$505 million–US$545 million and GAAP diluted EPS between a loss of US$0.13 and earnings of US$0.03,...

Caterpillar (CAT) is back in focus after its Power & Energy division posted 23% year over year sales growth, supported by demand for natural gas generators and battery storage from a broader customer base beyond traditional data center users. See our latest analysis for Caterpillar. Recent enthusiasm around Power & Energy has been reflected in the share price, with a 30 day share price return of 20.72% and a 90 day share price return of 33.51%. The 1 year total shareholder return of 126.27%...

Brady (BRC) is back in focus after reporting stronger than expected quarterly earnings, marking its 20th consecutive quarter of organic sales growth, raising full year earnings guidance, and emphasizing higher margin engineered products. See our latest analysis for Brady. The latest move in Brady's story is also showing up in the share price. The stock has a 1 month share price return of 8.60%, a 3 month share price return of 13.35% and a year to date share price return of 16.40%, while the 1...

Gentherm (THRM) is back in focus after reporting fourth quarter and full year 2025 results that showed much lower net income alongside record revenue, along with new revenue guidance for 2026 and 2027. See our latest analysis for Gentherm. The latest results and 2026 to 2027 revenue guidance came as the share price closed at $32.51, with a 1 day share price return of 4.69% decline and a 1 year total shareholder return of 4.35% decline. This points to pressure on the Gentherm story after...

UGI stock reacts to Q1 earnings and business reshaping UGI (UGI) is in focus after Q1 FY 2026 earnings, a major business reshaping in Europe, senior leadership changes, and expansion into new U.S. states drew fresh attention to the stock. See our latest analysis for UGI. At a share price of US$37.45, UGI has seen a 1 day share price return of 2.19% decline and a softer 7 day and 30 day share price return. However, its 1 year total shareholder return of 17.38% and 5 year total shareholder...

Stoke Therapeutics recently reported that it has dosed the first patient in its Phase 1 OSPREY trial of STK-002, an investigational antisense oligonucleotide designed to boost OPA1 protein expression and potentially treat Autosomal Dominant Optic Atrophy, a rare inherited cause of progressive, irreversible vision loss with no approved therapies. This first-in-human study moves Stoke’s TANGO platform into a new ophthalmic indication, offering an early real-world test of whether upregulating...

Ichor Holdings (ICHR) is drawing fresh attention after reporting strong Q4 results, issuing upbeat guidance for 2026, and receiving several analyst upgrades that highlight revenue growth projections and expected margin improvements under new leadership. See our latest analysis for Ichor Holdings. That Q4 beat and upbeat 2026 commentary come on top of powerful momentum in the share price, with a 30 day share price return of 62.60% and a year to date share price return of 150.32%. The 1 year...